Simvastatin Improves Survival After Variceal Bleeding in Cirrhosis: AJG | July 2026

Introduction:

Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This randomized trial evaluated whether adding simvastatin to standard therapy improves long-term outcomes after variceal bleeding.

Why was this study needed?

• Mortality remains high after acute variceal bleeding despite standard therapy.
• Evidence supporting statin use in decompensated cirrhosis is limited.
• Statins may improve portal hypertension and hepatic microcirculation beyond lipid lowering.
• Their long-term safety in cirrhosis remains uncertain.
• Randomized data evaluating survival benefit are lacking.

Results:

• Adding simvastatin to standard therapy significantly reduced all-cause mortality over 24 months compared with standard care alone.
• Simvastatin also reduced the development of new or refractory ascites and spontaneous bacterial peritonitis, while rates of rebleeding, hepatic encephalopathy, and acute-on-chronic liver failure were similar between groups.
• Serious adverse events were not increased, supporting the safety of low-dose simvastatin in appropriately selected patients with cirrhosis.

Clinical Impact:

This study provides important evidence that simvastatin may offer disease-modifying benefits in cirrhosis, extending beyond cholesterol reduction. When added to carvedilol and endoscopic band ligation, simvastatin improved survival without compromising safety, suggesting a potential role in secondary prophylaxis after variceal bleeding.

Bottom Line:

Low-dose simvastatin improved long-term survival after variceal bleeding in patients with cirrhosis while reducing ascites-related complications without increasing serious adverse events. Larger multicenter trials are warranted before routine incorporation into clinical practice.